Journal Article

SHP1 loss augments DLBCL cellular response to ibrutinib: a candidate predictive biomarker

Lu, Pin, Cai, Kathy Qi, Nejati, Reza, Ma, Ji, Poureghbali, Sahar, Lynn Wang, Y., Wu, Wenjun, Patel, Priyal, Nakhoda, Shazia R., Mallikarjuna, Vinay S.

2023

Overview

SHP1, a tyrosine phosphatase, negatively regulates B-cell receptor (BCR) signaling. Ibrutinib selectively inhibits BTK and has been approved for the treatment of several types of B-cell lymphomas, but not yet in diffuse large B-cell lymphoma (DLBCL). A phase 3 clinical trial of ibrutinib–containing regimen has been completed to evaluate its activity in subtypes or subsets of DLBCL patients. Although the subtype of activated B-cell like (ABC) DLBCL is characterized by chronic active BCR signaling, only a fraction of ABC-DLBCL patients seem to benefit from ibrutinib-containing regimen. New alternative predictive biomarkers are needed to identify patients who better respond. We investigated if SHP1 plays a role in defining the level of the BCR activity and impacts the response to ibrutinib. A meta-analysis revealed that lack of SHP1 protein expression as well as SHP1 promoter hypermethylation is strongly associated with NHL including DLBCL. On a tissue microarray of 95 DLBCL samples, no substantial difference in SHP1 expression was found between the GCB and non-GCB subtypes of DLBCL. However, we identified a strong reverse correlation between SHP1 expression and promoter methylation suggesting that promoter hypermethylation is responsible for SHP1 loss. SHP1 knockout in BCR-dependent GCB and ABC cell lines increased BCR signaling activities and sensitize lymphoma cells to the action of ibrutinib. Rescue of SHP1 in the knockout clones, on the other hand, restored BCR signaling and ibrutinib resistance. Further, pharmacological inhibition of SHP1 in both cell lines and patient-derived primary cells demonstrate that SHP1 inhibition synergized with ibrutinib in suppressing tumor cell growth. Thus, SHP1 loss may serve as an alternative biomarker to cell-of-origin to identify patients who potentially benefit from ibrutinib treatment. Our results further suggest that reducing SHP1 pharmacologically may represent a new strategy to augment tumor response to BCR-directed therapies. Schematic diagram summarizing the major findings. Left panel. When SHP1 is present and functional, it negatively regulates the activity of the BCR pathway. Right pane. When SHP1 is diminished or lost, cells depend more on the increased BCR signaling and making them vulnerable to BTK inhibitor, ibrutinib. Diagram was generated using BioRender.

• Publisher: Nature Publishing Group UK,Nature Publishing Group
• Subject: 13/1 / 13/31 / 13/44 / 13/95 / 38/23 / 631/67/1990/291/1621/1915 / 692/53/2423 / 82/51 / Apoptosis / B-cell lymphoma / B-cell receptor / Biomarkers / Cell Biology / Cell Line, Tumor / DNA methylation / Human Genetics / Humans / Inhibitor drugs / Internal Medicine / Lymphocytes B / Lymphoma / Lymphoma, Large B-Cell, Diffuse - drug therapy / Lymphoma, Large B-Cell, Diffuse - genetics / Lymphoma, Large B-Cell, Diffuse - metabolism / Medicine / Medicine & Public Health / Oncology / Patients / Protein Tyrosine Phosphatase, Non-Receptor Type 6 - genetics / Protein Tyrosine Phosphatase, Non-Receptor Type 6 - metabolism / Protein Tyrosine Phosphatase, Non-Receptor Type 6 - therapeutic use / Protein-tyrosine-phosphatase / SHP-1 protein / Signal Transduction / Targeted cancer therapy / Tumors